[Form 4] iTeos Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Matthew Gall, Chief Financial Officer of iTeos Therapeutics (ITOS), reported transactions tied to the company’s merger. At the effective time of the merger, each outstanding share was converted into $10.047 in cash plus one non-transferable contingent value right (CVR). The Form 4 reports the disposition/cancellation of 89,429 common shares and cancellation of multiple stock options and restricted stock units, with the filer showing 0 shares beneficially owned following the transactions. In-the-money options were canceled in exchange for cash equal to the difference between $10.047 and each option’s exercise price multiplied by the underlying shares, plus one CVR per share. The reported option and underlying share counts include 9,063, 135,937, 42,388, 8,123 and 252,135 units/options as described in the filing.

Positive

• Merger consideration is cash-based at a stated price of $10.047 per share, providing immediate liquidity to holders
• In-the-money options were cashed out, which removes potential future dilution tied to those options
• Accelerated vesting applied per plan terms, ensuring contractual treatment for affected service providers

Negative

• Reporting person reported 0 shares beneficially owned following the transaction, indicating full disposition of holdings disclosed here
• Large quantities of options and RSUs were canceled, which may concern stakeholders tracking executive equity retention post-transaction

Insights

Financial Analyst

TL;DR: Insider disposals reflect merger consideration conversion, not open-market sales; cash paid per share is $10.047 plus a CVR.

The Form 4 documents that the CFO’s equity holdings were settled under the merger agreement terms rather than through market trades. From a financial perspective, conversion at a fixed cash price simplifies payout valuation for these holdings; holders of in-the-money options received immediate cash equivalent value for intrinsic worth, reducing future dilution risk. The filings report substantial option and RSU cancellations, which removes those potential shares from future share count post-merger.

Corporate Governance Expert

TL;DR: The transactions follow contractually mandated merger mechanics and accelerated vesting provisions, raising no governance red flags on their face.

The disclosures indicate the Compensation Committee applied pre-agreed accelerated vesting and option cash-out provisions contained in the merger agreement. The treatment—cash payment plus CVRs for restricted stock units and in-the-money options—is standard in controlled M&A exits. Important governance items for stakeholders are disclosure clarity and confirmation that committee actions followed plan terms; the Form 4 provides those mechanics and volumes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gall Matthew

(Last) (First) (Middle)

C/O ITEOS THERAPEUTICS, INC.

321 ARSENAL STREET

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
iTeos Therapeutics, Inc. [ ITOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/29/2025		U(1)(2)(3)		89,429	D	(1)(2)(3)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.05	08/29/2025		D(4)			9,063	(4)(5)	(4)(5)	Common Stock	9,063	(4)(5)	0	D
Stock Option (Right to Buy)	$7.05	08/29/2025		D(4)			135,937	(4)(5)	(4)(5)	Common Stock	135,937	(4)(5)	0	D
Stock Option (Right to Buy)	$6.16	08/29/2025		D(5)			42,388	(5)	(5)	Common Stock	42,388	(5)	0	D
Stock Option (Right to Buy)	$6.16	08/29/2025		D(5)			8,123	(5)	(5)	Common Stock	8,123	(5)	0	D
Stock Option (Right to Buy)	$6.16	08/29/2025		D(5)			252,135	(5)	(5)	Common Stock	252,135	(5)	0	D

Explanation of Responses:

1. This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding Share was canceled and converted into the right to receive (i) $10.047 in cash per share (the "Cash Amount"); plus (ii) one non-transferable contractual contingent value right per share (each, a "CVR"), without interest and subject to applicable withholding of taxes.

2. The amount reported in Column 4 includes 65,000 restricted stock units of the Company ("Company Restricted Stock Units," and each such restricted stock unit, a "Company Restricted Stock Unit"). Pursuant to the actions of the of the Compensation and Leadership Development Committee of the Board of Directors of the Company (the "Committee") and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, (A) each Company Restricted Stock Unit that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with,

3. (Continued from footnote 2) or within a specified time following, a sale of the Company (each such Company Restricted Stock Unit, an "Accelerated Vesting Restricted Stock Unit") that was then outstanding but not then vested became immediately vested in full and (B) each Accelerated Vesting Restricted Stock Unit that was then outstanding was canceled and, in exchange therefor, the holder of such canceled Company Restricted Stock Unit became entitled to receive in consideration of the cancellation of such Company Restricted Stock Unit (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the Cash Amount and (y) one CVR.

4. Pursuant to the actions of the of the Committee and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company ("Company Stock Options," and each such option, a "Company Stock Option") that was then outstanding but not then vested or exercisable and that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or within a specified time following, a sale of the Company became immediately vested and exercisable in full.

5. In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option.

	/s/ Adi Osovsky, as Attorney-in-Fact	08/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why did ITOS insider transactions occur on 08/29/2025?

The transactions occurred at the effective time of the merger and reflect contractual conversion and cash-out provisions under the Merger Agreement.

How much cash did iTeos shareholders receive per share in the merger?

Shareholders received $10.047 in cash per issued and outstanding share, plus one CVR per share.

What happened to in-the-money options held by the reporting person?

In-the-money options were canceled and the holders received cash equal to (Cash Amount minus exercise price) multiplied by the underlying shares, plus one CVR per underlying share.

How many common shares did Matthew Gall dispose of according to the Form 4?

The Form 4 reports the disposition/cancellation of 89,429 common shares and shows 0 shares beneficially owned after the transaction.

Were restricted stock units accelerated and cashed out in the merger?

Yes. Accelerated Vesting Restricted Stock Units were vested and canceled at the Effective Time and converted into the cash amount per share plus one CVR per unit.